Merck & Co., Inc.: Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS =1)
Opinion Granted Based on Positive Results From Phase 3 KEYNOTE-826 Trial Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency's Committee
United States Peter Dannenbaum Damini Chokshi Melissa Moody Statement Of Merck Co Inc Exchange Commission
Source: finanznachrichten.de